Showing posts with label Their. Show all posts
Showing posts with label Their. Show all posts

Friday, August 18, 2017

How Drug Companies Need Their Patents


Today's post from burrillreport.com (see link below) is interesting because it shows us how drug companies are dependent on their patents for profits. In this case, the makers of Cymbalta (a common drug for the treatment of neuropathic symptoms), Ely Lilly have just lost their patent-exclusivity for Cymbalta and are therefore preparing for a big drop in revenue as other companies move in with alternatives to the drug. More competition is nearly always good news for the patient as it leads to greater choice and generally cheaper prices but there is another side to the story in that companies then have less revenue to invest in new research for newer drugs. It's how the pharmaceutical market works and considering their profit margins, we must be pleased when patents run out and alternatives become available. That said, neuropathy patients are still looking for the big breakthrough new drugs and that requires huge research funds, which are often generated by sales while current drugs are under patent. 

Eli Lilly Still Plans on Meeting 2014 Goals Company faces challenges, but is banking on new approvals and cost cutting.
DANIEL S. LEVINE The Burrill Report  October 03, 2013

“To reach its goals, Lilly says it is banking on targeted growth initiatives and the late-stage drugs in its pipeline.”

Eli Lilly told investors that despite the loss of revenue due to patent expirations for key drugs, it still plans on meeting its goals of generating at least $20 billion in revenue and $3 billion in profit for next year, returning to revenue growth and improving margins after that.

But to do so will be “challenging,” according to Lilly CFO Derica Rice, who noted that devaluation of the Yen and slower market growth in emerging market countries have diminished the company’s near-term expectations for sales growth. Rice says the company is finding appropriate ways to achieve its goals and will take additional actions to achieve its 2014 net income and operating cash flow targets through cutting expenses.

The comments came during a meeting with the investment community held at the company’s global headquarters in Indianapolis.

To reach its goals, Lilly says it is banking on targeted growth initiatives and the late-stage drugs in its pipeline. The company expects to launch several new drugs in 2014 with seven regulatory submissions for four different drugs made in 2013. This includes two drugs for type 2 diabetes and a drug for gastric cancer. The company also said it will make stock repurchases totaling $5 billion over time.

Lilly’s top-selling product, Cymbalta, for the treatment of major depressive disorder and general anxiety disorder, and pain associated with diabetic neuropathy, fibromyalgia and other chronic pain disorders lost patent exclusivity this year. Global sales of the drug accounted for roughly 25 percent of the company’s revenue in the last quarter, and generic selective serotonin and norepinephrine reuptake inhibitors on the market are predicted to reduce Lilly’s 2014 global revenue by 20 percent.

The company says its strategy to focus on development of innovative medicines has produced the strongest pipeline in its 137-year history, with 13 experimental drugs in late-stage clinical testing or in regulatory review and 26 more in mid-stage trials. That’s five times the number of candidates in mid-to-late-stage development than the company had in 2004.

“We’ve undertaken extensive efforts to transform our company to address the challenge of patent expirations and the demands of patients and payers for greater value from medicine,” says John Lechleiter, CEO of Lilly. “Today, we’re seeing our strategy bear fruit, backed by clinical data that strengthens our confidence in our innovation-based strategy and in our ability to return to growth.”


http://www.burrillreport.com/article-lilly_still_plans_on_meeting_2014_goals.html

Friday, July 28, 2017

ARTIFICIAL CELLS TAKE THEIR STEPS MOVABLE CYTOSKELETON MEMBRANE FABRICATED FOR THE FIRST TIME




 Using only a few ingredients, the biophysicist Prof. Andreas Bausch and his team at the Technische Universität München (TUM) have successfully implemented a minimalistic model of the cell that can change its shape and move on its own. They describe how they turned this goal into reality in the current edition of the journal Science, where their research is featured as cover story

Cells are complex objects with a sophisticated metabolic system. Their evolutionary ancestors, the primordial cells, were merely composed of a membrane and a few molecules. These were minimalistic yet perfectly functioning systems.
Thus, "back to the origins of the cell" became the motto of the group of TUM-Prof. Andreas Bausch, who is member of the cluster of excellence "Nanosystems Initiative Munich (NIM)" and his international partners. Their dream is to create a simple cell model with a specific function using a few basic ingredients. In this sense they are following the principle of synthetic biology in which individual cellular building blocks are assembled to create artificial biological systems with new characteristics.
The vision of the biophysicists was to create a cell-like model with a biomechanical function. It should be able to move and change its shape without external influences. They explain how they achieved this goal in their latest publication in Science.

The magic ball
The biophysicists' model comprises a membrane shell, two different kinds of biomolecules and some kind of fuel. The envelope, also known as a vesicle, is made of a double-layered lipid membrane, analogous of natural cell membranes. The scientists filled the vesicals with microtubules, tube-shaped components of the cytoskeleton, and kinesin molecules. In cells, kinesins normally function as molecular motors that transport cellular building blocks along the microtubules. In the experiment, these motors permanently push the tubules alongside each other. For this, kinesins require the energy carrier ATP, which was also available in the experimental setup.

From a physical perspective, the microtubules form a two-dimensional liquid crystal under the membrane, which is in a permanent state of motion. "One can picture the liquid crystal layer as tree logs drifting on the surface of a lake," explains Felix Keber, lead author of the study. "When it becomes too congested, they line up in parallel but can still drift alongside each other."

Migrating faults
Decisive for the deformation of the artificial cell construction is that, even in its state of rest, the liquid crystal must always contain faults. Mathematicians explain these kinds of phenomena by way of the Poincaré-Hopf theorem, figuratively also referred to as the "hairy ball problem." Just as one can't comb a hairy ball flat without creating a cowlick, there will always be some microtubules that cannot lay flat against the membrane surface in a regular pattern. At certain locations the tubules will be oriented somewhat orthogonally to each other -- in a very specific geometry. Since the microtubules in the case of the Munich researchers are in constant motion alongside each other due to the activity of the kinesin molecules, the faults also migrate. Amazingly, they do this in a very uniform and periodic manner, oscillating between two fixed orientations.

Spiked extensions
As long as the vesicle has a spherical shape, the faults have no influence on the external shape of the membrane. However, as soon as water is removed through osmosis, the vesicle starts to change in shape due to the movement within the membrane. As the vesicle loses ever more water, slack in the membrane forms into spiked extensions like those used by single cells for locomotion.
In this process, a fascinating variety of shapes and dynamics come to light. What seems random at first sight is, in fact, following the laws of physics. This is how the international scientists succeeded in deciphering a number of basic principles like the periodic behavior of the vesicles. These principles, in turn, serve as a basis for making predictions in other systems.

"With our synthetic biomolecular model we have created a novel option for developing minimal cell models," explains Bausch. "It is ideally suited to increasing the complexity in a modular fashion in order to reconstruct cellular processes like cell migration or cell division in a controlled manner. That the artificially created system can be comprehensively described from a physical perspective gives us hope that in the next steps we will also be able to uncover the basic principles behind the manifold cell deformations."





Thursday, June 29, 2017

Avelox Levaquin And Cipro Facing Their Day In Court


Today's post from aboutlawsuits.com (see link below) takes us back to an older problem for potential neuropathy sufferers and that is nerve damage cause by fluoroquinolone antibiotics. Despite it seeming like an age since this was first highlighted, the subject is finally reaching the courts and hopefully, pharmaceutical companies will now be held responsible for the damage they've caused (and continue to cause). This article is a news update but also a continued warning about fluoroquinolones and nerve damage. It's a warning you would do well to heed because doctors across the world still blithely prescribe these pills, seemingly unaware of the dangers. There are many other articles on this subject here on the blog - use the search button to find them and then make your own minds up (or at least have a serious discussion with your prescribing doctor). There are always alternatives to fluoroquinolones (the main brand names are mentioned below) but you may need to point this out to your doctor.

Lawsuit Over Peripheral Neuropathy from Avelox, Levaquin and Cipro Filed by 48 Plaintiffs
November 18, 2016 Written by: Irvin Jackson
 
A group of 48 plaintiffs have filed a joint lawsuit indicating that they have been left with peripheral neuropathy from Levaquin, Avelox and Cipro antibiotic treatments, suffering painful and debilitating nerve damage.

The complaint (PDF) was filed late last month in the U.S. District Court for the Western District of Oklahoma, naming Bayer Healthcare, Merck & Co., Johnson & Johnson and its Janssen subsidiary as defendants.

Each of the plaintiffs indicate they developed a form of nerve damage known as peripheral neuropathy, with some of the plaintiffs experiencing fatal injuries.

Peripheral neuropathy involves damage to the nerves that may impair sensation, movement and other aspects of health. This typically leaves users with persistent pain, burning, tingling, numbness, weakness and sensitivity to light touches, temperature and motion in the arms and legs, as well as other problems that cause a major disruption to daily activities.

The case joins hundreds of other Levaquin lawsuits, Avelox lawsuits and Cipro lawsuits filed on behalf of individuals nationwide, each raising similar allegations that the drug makers failed to provide adequate warnings for users and the medical community about the risk of permanent peripheral neuropathy from the antibiotics, which may continue long after the medication is no longer used.

Prior warnings provided with the medications, which are part of a class of drugs known as fluoroquinolones, suggested that reports of nerve damage were rare and typically resolved after the drug was no longer used. However, the FDA required the manufacturers to update the warning label in August 2013, indicating that in many cases that peripheral neuropathy from Avelox, Levaquin and Cipro is permanent.

“[R]ather than warning patients and physicians that the use of Fluoroquinolones may result in permanent nerve damage, Defendants instead adopted a warning that misleadingly indicated such damage was rare and in any event could be avoided by simply discontinuing the drug upon the onset of certain symptoms,” the joint lawsuit filed last month on behalf of nearly 50 people states. “Defendants’ failure to adequately warn physicians resulted in (1) patients receiving Fluoroquinolones instead of another acceptable and adequate non-fluoroquinolone antibiotic, sufficient to treat the illness for which Plaintiffs presented to the provider; (2) and physicians failing to warn and instruct consumers about the risk of peripheral nervous system injuries associated with Fluoroquinolones.”

Given the risk of nerve damage and other injuries associated with the antibiotics, the FDA issued a new drug safety communication in May 2016, urging doctors not to prescribe Avelox, Levaquin, Cipro or other fluoroquinolones for many common infections that are uncomplicated and have other available treatment options, indicating that the risks associated with the antibiotics outweigh the benefits. The federal regulatory agency considered available information on the risk of peripheral neuropathy, tendon ruptures, retinal detachments and other health concerns linked to the drugs at that time.
Antibiotic Peripheral Neuropathy Lawsuits

This recent complaint will be consolidated with about 600 other claims pending in the federal court system, which are centralized for pretrial proceedings before U.S. District Judge John R. Tunheim in the District of Minnesota, as part of an MDL, or Multidistrict Litigation.

Given similar questions of fact and law raised in the lawsuits over peripheral neuropathy from the antibiotics, the cases are being coordinated during discovery, bellwether trials and other pretrial litigation.

Judge Tunheim will hold a “Science Day” in the peripheral neuropathy litigation in January 2017, at which time the parties will present scientific information in a non-adversarial manner designed to educate the court about issues that will come up in the litigation.

It is expected that a small group of cases in the MDL will ultimately be selected for a series of “bellwether” trials, which are designed to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout a number of claims. While the outcomes of these early trial dates are not binding on other claims, they may help facilitate potential peripheral neuropathy settlements for individuals who have been left with the severe and debilitating nerve damage from Avelox, Levaquin or Cipro.

As the peripheral neuropathy cases move forward, the drug makers also face an increasing number of aortic aneurysm lawsuits and aortic dissection lawsuits that are being investigated by individuals nationwide, as recent studies have suggested that medications may cause collagen degradation issues throughout the body, impacting the aorta.

Plaintiffs in those cases point out that users and doctors have never been provided any warning about the risk of an aortic aneurysm or dissection from Avelox, Levaquin or Cipro.

Related Stories
Avelox Nerve Damage Lawsuit Filed Over Failure to Warn About Antibiotic Risks (8/12/2016)
Antibiotic Peripheral Neuropathy Lawsuits Will Not Be Designated as Mass Tort in Philly (2/8/2016)
Levaquin Lawsuit Over Nerve Damage Alleges J&J Violated RICO Act (1/22/2016)
Fluoroquinolone Antibiotic Side Effects Warrant Stronger Warnings: FDA Panel (11/9/2015)
Levaquin, Cipro, Avelox Risks Pose A Concern In Face of Modest Benefits: FDA Reviewers (11/4/2015)


http://www.aboutlawsuits.com/lawsuit-peripheral-neuropathy-avelox-levaquin-114067/

Thursday, June 8, 2017

Some Neuropathies And Their Causes


Today's short post from lifeinthefastlane.com (see link below) should make you smile at least! It's basically a list of forms and causes of neuropathy and his use of acronyms is creative but will probably make you remember them. You may need further information concerning one or more of these categories - if that's the case, then Google is your best friend (followed by the search button on this blog!).
 


Peripheral neuropathy Chris Nickson 2016

Overview
Diseases that affect the the peripheral nerves, either motor or sensory
Important subgroups for differential diagnosis are: predominately motor, painful peripheral neuropathies and mononeuritis multiplex
Mononeuritis multiplex is a painful, asymmetrical, asynchronous sensory and motor peripheral neuropathy involving isolated damage to at least 2 separate nerve areas that can be in random areas of the body.


Causes

Peripheral neuropathies

“DAM IT BICH” 

 
drugs and toxins – e.g. heavy metals, isoniazid, vincristine, phenytoin, nitrofurantoin, cis-platinum, amiodarone, larges of vitamin B6,
alcohol and amyloid
metabolic – e.g. DM (30%), acromegaly, hypothyroidism
infectious/post- – e.g. Lyme, diptheria, GBS
tumor – e.g. lung CA
B12, B1, B5 or B6 deficiency
idiopathic (30%)
CTD or vasculitis, e.g. SLE, PAN
hereditary (30%)

or the alternative “DAM IT BITCH”: 

 
D Drugs and chemicals (Pb, phenytoin, metronidazole, amiodarone, hydralazine, vincristine, isoniazid, organic solvents, sulphonamides, nitrofurantoin, CO, OPs).
A alcohol (with or without Thiamine deficiency)
M metabolic (diabetes, hypoglycemia, uraemia)
I infection (HIV, leprosy, lyme, diptheria, syphilis) or post infectious (GBS)
T tumour (paraneoplastic phenomenon – lung, lymphoma, myeloma)
B B12 & other vitamin deficiency states, as well as pyridoxine excess
I idiopathic and infiltrative (e.g. amyloidosis)
T toxins (botulism, ciguatera, Tetrodotoxin, Saxitoxin, BRO, tick paralysis)
C connective tissue diseases (e.g. SLE, PAN, RhA) and congenital (e.g. CMT)
H Hypothyroidism

Predominately motor peripheral neuropathy

 
Guillain-Barré syndrome, chronic inflammatory polyradiculoneuropathy
Hereditary motor and sensory neuropathy
Diabetes mellitus
Others-e.g. acute intermittent porphyria, lead poisoning, diphtheria, multifocal conduction block neuropathy

Painful peripheral neuropathy

“BADCAP”
Diabetes mellitus
Alcohol
Vitamin B1 or B12 deficiency
Carcinoma
Porphyria
Arsenic or thallium poisoning

Mononeuritis multiplex

Acute 

 
Daibetes mellitus
Polyarteritis nodosum
Connective tissue diseases, e.g. SLE, Rheumatoid arthrits

Chronic 

 
multiple compressive neuropathies
sarcoidosis
acromegaly
leprosy
Lyme disease
idiopathic

Polyneuropathies with autonomic involvement

These are the common ones:

 
diabetes mellitus
amyloidosis
Guillain-Barre Syndrome
Paraneoplastic neuropathy (usually lung cancer)
Sogren’s syndrome-associated neuropathy
References and Links

Journal Articles and Textbooks

Burns JM, Mauermann ML, Burns TM. An easy approach to evaluating peripheral neuropathy. J Fam Pract. 2006 Oct;55(10):853-61. Review. PubMed PMID: 17014750. [Free Full Text]
Talley NJ, O’Connor S. Clinical Examination: A Systematic Guide to Physical Diagnosis. MacLennan and Petty. 3rd edition, 1998.

About Chris Nickson

An oslerphile emergency physician and intensivist suffering from a bad case of knowledge dipsosis. Key areas of interest include: the ED-ICU interface, toxicology, simulation and the free open-access meducation (FOAM) revolution. @Twitter | + Chris Nickson | RAGE | INTENSIVE| SMACC | iTeachEM

http://lifeinthefastlane.com/resources/peripheral-neuropathy-ddx/